Immunophenotyping of PBMCs from patients with CVID
. | CD3 . | . | CD4 . | . | CD8 . | . | CD45RA . | . | CD45RO . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | % of PBLs . | MFI* . | % of PBLs . | MFI* . | % of CD3†PBLs . | MFI* . | % of CD3†PBLs . | MFI* . | % of CD3†PBLs . | MFI* . | |||||
| Control | 83.8 ± 2 | 235.4 ± 4.9 | 44.6 ± 0.2 | 260.4 ± 56.0 | 33.0 ± 4.7 | 802.0 ± 56.0 | 43.2 ± 7.1 | 116.6 ± 11.5 | 46.7 ± 2.7 | 123.7 ± 15.1 | |||||
| 1 | 81.5 | 190.7 | 31.4 | 253.5 | 54.1 | 877.6 | 49.8 | 130.5 | 43.9 | 98.5 | |||||
| 2 | 74.4 | 211.5 | 28.7 | 266.0 | 45.5 | 686.1 | 41.7 | 226.6 | 53.4 | 179.3 | |||||
| 3 | 90.8 | 211.8 | 34.1 | 284.6 | 56.6 | 786.7 | 55.4 | 123.9 | 40.6 | 154.6 | |||||
| 4 | 87.7 | 243.2 | 28.1 | 326.8 | 55.5 | 908.6 | 33.0 | 135.6 | 54.2 | 174.5 | |||||
| 5 | 88.4 | 221.3 | 46.2 | 271.3 | 41.4 | 720.6 | 57.4 | 150.4 | 41.3 | 180.7 | |||||
| 6 | 91.1 | 210.7 | 35.1 | 260.2 | 58.7 | 680.2 | 50.7 | 163.5 | 40.5 | 176.4 | |||||
. | CD3 . | . | CD4 . | . | CD8 . | . | CD45RA . | . | CD45RO . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | % of PBLs . | MFI* . | % of PBLs . | MFI* . | % of CD3†PBLs . | MFI* . | % of CD3†PBLs . | MFI* . | % of CD3†PBLs . | MFI* . | |||||
| Control | 83.8 ± 2 | 235.4 ± 4.9 | 44.6 ± 0.2 | 260.4 ± 56.0 | 33.0 ± 4.7 | 802.0 ± 56.0 | 43.2 ± 7.1 | 116.6 ± 11.5 | 46.7 ± 2.7 | 123.7 ± 15.1 | |||||
| 1 | 81.5 | 190.7 | 31.4 | 253.5 | 54.1 | 877.6 | 49.8 | 130.5 | 43.9 | 98.5 | |||||
| 2 | 74.4 | 211.5 | 28.7 | 266.0 | 45.5 | 686.1 | 41.7 | 226.6 | 53.4 | 179.3 | |||||
| 3 | 90.8 | 211.8 | 34.1 | 284.6 | 56.6 | 786.7 | 55.4 | 123.9 | 40.6 | 154.6 | |||||
| 4 | 87.7 | 243.2 | 28.1 | 326.8 | 55.5 | 908.6 | 33.0 | 135.6 | 54.2 | 174.5 | |||||
| 5 | 88.4 | 221.3 | 46.2 | 271.3 | 41.4 | 720.6 | 57.4 | 150.4 | 41.3 | 180.7 | |||||
| 6 | 91.1 | 210.7 | 35.1 | 260.2 | 58.7 | 680.2 | 50.7 | 163.5 | 40.5 | 176.4 | |||||
Controls include 6 age- and sex-matched healthy donors. Error measurements are mean ± SD. MFI indicates mean fluorescence intensity.
MFI obtained through 2-color flow cytometric analysis of PBMCs from 2 representative healthy donors and 4 patients with CVID.
MFI obtained through 3-color flow cytometric analysis of PBMCs from 3 representative healthy donors and 4 patients with CVID. Data refer to CD3+ cells.